Dupuytren’s Disease Market Size, Share & Trends Analysis Report By Type (Diagnosis, Treatment), By Disease Type (Type I, Type II), By End-use (Hospitals, Clinics), By Region (Europe, Asia Pacific), And Segment Forecasts, 2023 - 2030
This report can be delivered to the clients within 3 Business Days
Dupuytren’s Disease Market Growth & Trends
The global dupuytren’s disease market size is expected to reach USD 5.87 billion by 2030, registering a CAGR of 4.55% from 2023 to 2030, according to a new report by Grand View Research, Inc. Dupuytren’s disease is a debilitating condition characterized by the abnormal thickening and shortening of palm tissue, leading to the formation of claw-like finger deformities. This projected market expansion highlights the growing recognition of the importance of addressing and treating this condition effectively. The industry presents lucrative prospects for stakeholders, such as pharmaceutical companies, medical device manufacturers, and healthcare providers to develop innovative therapies and interventions. As the prevalence of the condition continues to rise, there is an escalating demand for effective treatments that can improve symptoms and enhance patients' quality of life.
Consequently, intensified research and development efforts are anticipated in the near future, leading to advancements in treatment options and potential breakthroughs in managing Dupuytren's disease. In a recent study, adalimumab emerged as a potentially cost-effective treatment choice during the early stages of Dupuytren’s disease. The research findings suggest that this medication holds promise in effectively managing the condition while providing value for the investment. These results underscore the potential advantages of adalimumab as a practical and economically viable treatment option specifically for individuals in the early stages of Dupuytren’s disease. The growing awareness and understanding of the disease among healthcare professionals and patients, along with advancements in medical research and diagnostics, are driving the market expansion.
Improved detection rates and timely intervention have increased the demand for effective treatments. Endo Pharmaceuticals’ “Watching Education Unfold” campaign, featuring real patients, aims to raise awareness about Dupuytren’s contracture and educate the public and healthcare community about the condition and available treatment options. This initiative is expected to contribute to heightened awareness, early diagnosis, and improved management of contractures. In addition, significant advancements in medical technology and therapeutic approaches, such as injectable collagenase and minimally invasive surgical techniques, have played a crucial role in driving the market forward. Injectable collagenase treatment like Xiaflex has gained approval for Dupuytren's contracture in multiple countries, offering a less invasive alternative to traditional surgical procedures and leading to improved patient outcomes and shorter recovery times. These advancements in medical technology and therapeutics are significant contributors to the overall growth of the market.
Dupuytren’s Disease Market Report Highlights
Dupuytren’s Disease Market Growth & Trends
The global dupuytren’s disease market size is expected to reach USD 5.87 billion by 2030, registering a CAGR of 4.55% from 2023 to 2030, according to a new report by Grand View Research, Inc. Dupuytren’s disease is a debilitating condition characterized by the abnormal thickening and shortening of palm tissue, leading to the formation of claw-like finger deformities. This projected market expansion highlights the growing recognition of the importance of addressing and treating this condition effectively. The industry presents lucrative prospects for stakeholders, such as pharmaceutical companies, medical device manufacturers, and healthcare providers to develop innovative therapies and interventions. As the prevalence of the condition continues to rise, there is an escalating demand for effective treatments that can improve symptoms and enhance patients' quality of life.
Consequently, intensified research and development efforts are anticipated in the near future, leading to advancements in treatment options and potential breakthroughs in managing Dupuytren's disease. In a recent study, adalimumab emerged as a potentially cost-effective treatment choice during the early stages of Dupuytren’s disease. The research findings suggest that this medication holds promise in effectively managing the condition while providing value for the investment. These results underscore the potential advantages of adalimumab as a practical and economically viable treatment option specifically for individuals in the early stages of Dupuytren’s disease. The growing awareness and understanding of the disease among healthcare professionals and patients, along with advancements in medical research and diagnostics, are driving the market expansion.
Improved detection rates and timely intervention have increased the demand for effective treatments. Endo Pharmaceuticals’ “Watching Education Unfold” campaign, featuring real patients, aims to raise awareness about Dupuytren’s contracture and educate the public and healthcare community about the condition and available treatment options. This initiative is expected to contribute to heightened awareness, early diagnosis, and improved management of contractures. In addition, significant advancements in medical technology and therapeutic approaches, such as injectable collagenase and minimally invasive surgical techniques, have played a crucial role in driving the market forward. Injectable collagenase treatment like Xiaflex has gained approval for Dupuytren's contracture in multiple countries, offering a less invasive alternative to traditional surgical procedures and leading to improved patient outcomes and shorter recovery times. These advancements in medical technology and therapeutics are significant contributors to the overall growth of the market.
Dupuytren’s Disease Market Report Highlights
- The type II disease segment dominated the market in 2022 due to its higher prevalence, more severe symptoms, and greater demand for treatment options
- In addition, advancements in medical technology have focused on addressing challenges specific to type II Dupuytren's disease, leading to a wider range of effective treatments available for patients
- By type, the treatment segment held a dominant revenue share in 2022 due to the increasing demand for effective treatment options to alleviate symptoms and improve the quality of life for individuals
- The hospitals end-use segment held the largest market share in 2022 due to advanced infrastructure, specialized care, and referral networks
- Europe established a strong regional position in the market in 2022. This can be attributed to factors, such as advanced healthcare infrastructure, increasing prevalence of the disease, and presence of key players driving innovation and access to treatment options in the region
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Objectives
1.2.1. Objective -
1.2.2. Objective -
1.2.3. Objective -
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Gvr’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Disease Type and Type Snapshot
2.3. End-use Snapshot
2.4. Competitive Landscape Snapshot
CHAPTER 3. MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Increasing Prevalence
3.4.2. Rising Awareness and Diagnosis Rates
3.4.3. High Adoption in Treatment
3.5. Market Restraint Analysis
3.5.1. Limited Curative Treatment Options
3.5.2. High Treatment Cost
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
3.6.2. Porter’s Five Forces Analysis
3.7. COVID-19 Impact Analysis
CHAPTER 4. DISEASE TYPE BUSINESS ANALYSIS
4.1. Dupuytren’s Disease Market: Disease Type Movement Analysis
4.2. Type I
4.2.1. Type I Market, 2018 - 2030 (USD Million)
4.3. Type II
4.3.1. Type II Market, 2018 - 2030 (USD Million)
4.4. Type III
4.4.1. Type III Market, 2018 - 2030 (USD Million)
CHAPTER 5. TYPE BUSINESS ANALYSIS
5.1. Dupuytren’s Disease Market: Disease Type Movement Analysis
5.2. Diagnosis
5.2.1. Diagnosis Market, 2018 - 2030 (USD Million)
5.2.2. Physical Examination
5.2.2.1. Physical Examination Market, 2018 - 2030 (USD Million)
5.2.3. X-ray
5.2.3.1. X-ray Market, 2018 - 2030 (USD Million)
5.3. Treatment
5.3.1. Treatment Market, 2018 - 2030 (USD Million)
5.3.2. Surgery
5.3.2.1. Surgery Market, 2018 - 2030 (USD Million)
5.3.3. Radiation Therapy
5.3.3.1. Radiation Therapy Market, 2018 - 2030 (USD Million)
5.3.4. Needle Aponeurotomy
5.3.4.1. Needle Aponeurotomy Market, 2018 - 2030 (USD Million)
5.3.5. Steroid Short
5.3.5.1. Steroid Short Market, 2018 - 2030 (USD Million)
5.3.6. Enzyme Injection
5.3.6.1. Enzyme Injection Market, 2018 - 2030 (USD Million)
5.3.7. Occupational Therapy
5.3.7.1. Occupational Therapy Market, 2018 - 2030 (USD Million)
5.3.8. Others
5.3.8.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 6. END-USE BUSINESS ANALYSIS
6.1. Dupuytren’s Disease Market Segmentation: End-Use Movement Analysis
6.2. Hospitals
6.2.1. Hospitals Market, 2018 - 2030 (USD Million)
6.3. Clinics
6.3.1. Clinics Market, 2018 - 2030 (USD Million)
6.4. Academic & Research Institutes
6.4.1. Academic And Research Institutes Market, 2018 - 2030 (USD Million)
6.5. Others
6.5.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 7. REGIONAL BUSINESS ANALYSIS
7.1. Dupuytren’s Disease Market Share By Region, 2022 & 2030
7.2. North America
7.2.1. SWOT Analysis
7.2.2. North America Dupuytren’s Disease, 2018 - 2030 (USD Million)
7.2.3. U.S.
7.2.3.1. Key Country Dynamics
7.2.3.2. Target Disease Prevalence
7.2.3.3. Competitive Scenario
7.2.3.4. Regulatory Framework
7.2.3.5. U.S. Dupuytren’s Disease, 2018 - 2030 (USD Million)
7.2.4. Canada
7.2.4.1. Key Country Dynamics
7.2.4.2. Target Disease Prevalence
7.2.4.3. Competitive Scenario
7.2.4.4. Regulatory Framework
7.2.4.5. Canada Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. SWOT Analysis
7.3.2. Europe Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.3.3. UK
7.3.3.1. Key Country Dynamics
7.3.3.2. Target Disease Prevalence
7.3.3.3. Competitive Scenario
7.3.3.4. Regulatory Framework
7.3.3.5. UK Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.3.4. Germany
7.3.4.1. Key Country Dynamics
7.3.4.2. Target Disease Prevalence
7.3.4.3. Competitive Scenario
7.3.4.4. Regulatory Framework
7.3.4.5. Germany Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.3.5. France
7.3.5.1. Key Country Dynamics
7.3.5.2. Target Disease Prevalence
7.3.5.3. Competitive Scenario
7.3.5.4. Regulatory Framework
7.3.5.5. France Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.3.6. Italy
7.3.6.1. Key Country Dynamics
7.3.6.2. Target Disease Prevalence
7.3.6.3. Competitive Scenario
7.3.6.4. Regulatory Framework
7.3.6.5. Italy Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.3.7. Spain
7.3.7.1. Key Country Dynamics
7.3.7.2. Target Disease Prevalence
7.3.7.3. Competitive Scenario
7.3.7.4. Regulatory Framework
7.3.7.5. Spain Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.3.8. Denmark
7.3.8.1. Key Country Dynamics
7.3.8.2. Target Disease Prevalence
7.3.8.3. Competitive Scenario
7.3.8.4. Regulatory Framework
7.3.8.5. Denmark Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.3.9. Sweden
7.3.9.1. Key Country Dynamics
7.3.9.2. Target Disease Prevalence
7.3.9.3. Competitive Scenario
7.3.9.4. Regulatory Framework
7.3.9.5. Sweden Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.3.10. Norway
7.3.10.1. Key Country Dynamics
7.3.10.2. Target Disease Prevalence
7.3.10.3. Competitive Scenario
7.3.10.4. Regulatory Framework
7.3.10.5. Norway Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. SWOT Analysis
7.4.2. Asia Pacific Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Competitive Scenario
7.4.3.4. Regulatory Framework
7.4.3.5. Japan Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.4.4. China
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Competitive Scenario
7.4.4.4. Regulatory Framework
7.4.4.5. China Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.4.5. India
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Competitive Scenario
7.4.5.4. Regulatory Framework
7.4.5.5. India Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Competitive Scenario
7.4.6.4. Regulatory Framework
7.4.6.5. Australia Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Competitive Scenario
7.4.7.4. Regulatory Framework
7.4.7.5. Thailand Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.4.8. South Korea
7.4.8.1. Key Country Dynamics
7.4.8.2. Target Disease Prevalence
7.4.8.3. Competitive Scenario
7.4.8.4. Regulatory Framework
7.4.8.5. South Korea Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. SWOT Analysis
7.5.2. Latin America Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.5.3. Brazil
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Competitive Scenario
7.5.3.4. Regulatory Framework
7.5.3.5. Brazil Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.5.4. Mexico
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Competitive Scenario
7.5.4.4. Regulatory Framework
7.5.4.5. Mexico Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.5.5. Argentina
7.5.5.1. Key Country Dynamics
7.5.5.2. Target Disease Prevalence
7.5.5.3. Competitive Scenario
7.5.5.4. Regulatory Framework
7.5.5.5. Argentina Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.6. MEA
7.6.1. SWOT Analysis
7.6.2. MEA Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.6.3. South Africa
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Competitive Scenario
7.6.3.4. Regulatory Framework
7.6.3.5. South Africa Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.6.4. Saudi Arabia
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Competitive Scenario
7.6.4.4. Regulatory Framework
7.6.4.5. Saudi Arabia Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.6.5. UAE
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Competitive Scenario
7.6.5.4. Regulatory Framework
7.6.5.5. UAE Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.6.6. Kuwait
7.6.6.1. Key Country Dynamics
7.6.6.2. Target Disease Prevalence
7.6.6.3. Competitive Scenario
7.6.6.4. Regulatory Framework
7.6.6.5. Kuwait Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share Analysis, 2022
8.4. Company Profiles/Listing
8.4.1. Bayer AG.
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Novartis AG
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Pfizer Inc
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Nantong Jinghua Pharmaceutical Co., Ltd
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Actiza Pharmaceutical Private Limited
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Endo International plc
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Bristol-Meyers Squibb Company
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Spear Pharmaceuticals
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. GSK plc
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. AstraZeneca
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives
8.4.11. Hikma Pharmaceuticals PLC
8.4.11.1. Overview
8.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.11.3. Product Benchmarking
8.4.11.4. Strategic Initiatives
8.4.12. LEO Pharma A/S
8.4.12.1. Overview
8.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.12.3. Product Benchmarking
8.4.12.4. Strategic Initiatives
8.4.13. Fresenius Kabi AG
8.4.13.1. Overview
8.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.13.3. Product Benchmarking
8.4.13.4. Strategic Initiatives
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Objectives
1.2.1. Objective -
1.2.2. Objective -
1.2.3. Objective -
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Gvr’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Disease Type and Type Snapshot
2.3. End-use Snapshot
2.4. Competitive Landscape Snapshot
CHAPTER 3. MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Increasing Prevalence
3.4.2. Rising Awareness and Diagnosis Rates
3.4.3. High Adoption in Treatment
3.5. Market Restraint Analysis
3.5.1. Limited Curative Treatment Options
3.5.2. High Treatment Cost
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
3.6.2. Porter’s Five Forces Analysis
3.7. COVID-19 Impact Analysis
CHAPTER 4. DISEASE TYPE BUSINESS ANALYSIS
4.1. Dupuytren’s Disease Market: Disease Type Movement Analysis
4.2. Type I
4.2.1. Type I Market, 2018 - 2030 (USD Million)
4.3. Type II
4.3.1. Type II Market, 2018 - 2030 (USD Million)
4.4. Type III
4.4.1. Type III Market, 2018 - 2030 (USD Million)
CHAPTER 5. TYPE BUSINESS ANALYSIS
5.1. Dupuytren’s Disease Market: Disease Type Movement Analysis
5.2. Diagnosis
5.2.1. Diagnosis Market, 2018 - 2030 (USD Million)
5.2.2. Physical Examination
5.2.2.1. Physical Examination Market, 2018 - 2030 (USD Million)
5.2.3. X-ray
5.2.3.1. X-ray Market, 2018 - 2030 (USD Million)
5.3. Treatment
5.3.1. Treatment Market, 2018 - 2030 (USD Million)
5.3.2. Surgery
5.3.2.1. Surgery Market, 2018 - 2030 (USD Million)
5.3.3. Radiation Therapy
5.3.3.1. Radiation Therapy Market, 2018 - 2030 (USD Million)
5.3.4. Needle Aponeurotomy
5.3.4.1. Needle Aponeurotomy Market, 2018 - 2030 (USD Million)
5.3.5. Steroid Short
5.3.5.1. Steroid Short Market, 2018 - 2030 (USD Million)
5.3.6. Enzyme Injection
5.3.6.1. Enzyme Injection Market, 2018 - 2030 (USD Million)
5.3.7. Occupational Therapy
5.3.7.1. Occupational Therapy Market, 2018 - 2030 (USD Million)
5.3.8. Others
5.3.8.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 6. END-USE BUSINESS ANALYSIS
6.1. Dupuytren’s Disease Market Segmentation: End-Use Movement Analysis
6.2. Hospitals
6.2.1. Hospitals Market, 2018 - 2030 (USD Million)
6.3. Clinics
6.3.1. Clinics Market, 2018 - 2030 (USD Million)
6.4. Academic & Research Institutes
6.4.1. Academic And Research Institutes Market, 2018 - 2030 (USD Million)
6.5. Others
6.5.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 7. REGIONAL BUSINESS ANALYSIS
7.1. Dupuytren’s Disease Market Share By Region, 2022 & 2030
7.2. North America
7.2.1. SWOT Analysis
7.2.2. North America Dupuytren’s Disease, 2018 - 2030 (USD Million)
7.2.3. U.S.
7.2.3.1. Key Country Dynamics
7.2.3.2. Target Disease Prevalence
7.2.3.3. Competitive Scenario
7.2.3.4. Regulatory Framework
7.2.3.5. U.S. Dupuytren’s Disease, 2018 - 2030 (USD Million)
7.2.4. Canada
7.2.4.1. Key Country Dynamics
7.2.4.2. Target Disease Prevalence
7.2.4.3. Competitive Scenario
7.2.4.4. Regulatory Framework
7.2.4.5. Canada Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. SWOT Analysis
7.3.2. Europe Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.3.3. UK
7.3.3.1. Key Country Dynamics
7.3.3.2. Target Disease Prevalence
7.3.3.3. Competitive Scenario
7.3.3.4. Regulatory Framework
7.3.3.5. UK Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.3.4. Germany
7.3.4.1. Key Country Dynamics
7.3.4.2. Target Disease Prevalence
7.3.4.3. Competitive Scenario
7.3.4.4. Regulatory Framework
7.3.4.5. Germany Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.3.5. France
7.3.5.1. Key Country Dynamics
7.3.5.2. Target Disease Prevalence
7.3.5.3. Competitive Scenario
7.3.5.4. Regulatory Framework
7.3.5.5. France Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.3.6. Italy
7.3.6.1. Key Country Dynamics
7.3.6.2. Target Disease Prevalence
7.3.6.3. Competitive Scenario
7.3.6.4. Regulatory Framework
7.3.6.5. Italy Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.3.7. Spain
7.3.7.1. Key Country Dynamics
7.3.7.2. Target Disease Prevalence
7.3.7.3. Competitive Scenario
7.3.7.4. Regulatory Framework
7.3.7.5. Spain Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.3.8. Denmark
7.3.8.1. Key Country Dynamics
7.3.8.2. Target Disease Prevalence
7.3.8.3. Competitive Scenario
7.3.8.4. Regulatory Framework
7.3.8.5. Denmark Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.3.9. Sweden
7.3.9.1. Key Country Dynamics
7.3.9.2. Target Disease Prevalence
7.3.9.3. Competitive Scenario
7.3.9.4. Regulatory Framework
7.3.9.5. Sweden Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.3.10. Norway
7.3.10.1. Key Country Dynamics
7.3.10.2. Target Disease Prevalence
7.3.10.3. Competitive Scenario
7.3.10.4. Regulatory Framework
7.3.10.5. Norway Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. SWOT Analysis
7.4.2. Asia Pacific Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Competitive Scenario
7.4.3.4. Regulatory Framework
7.4.3.5. Japan Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.4.4. China
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Competitive Scenario
7.4.4.4. Regulatory Framework
7.4.4.5. China Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.4.5. India
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Competitive Scenario
7.4.5.4. Regulatory Framework
7.4.5.5. India Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Competitive Scenario
7.4.6.4. Regulatory Framework
7.4.6.5. Australia Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Competitive Scenario
7.4.7.4. Regulatory Framework
7.4.7.5. Thailand Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.4.8. South Korea
7.4.8.1. Key Country Dynamics
7.4.8.2. Target Disease Prevalence
7.4.8.3. Competitive Scenario
7.4.8.4. Regulatory Framework
7.4.8.5. South Korea Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. SWOT Analysis
7.5.2. Latin America Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.5.3. Brazil
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Competitive Scenario
7.5.3.4. Regulatory Framework
7.5.3.5. Brazil Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.5.4. Mexico
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Competitive Scenario
7.5.4.4. Regulatory Framework
7.5.4.5. Mexico Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.5.5. Argentina
7.5.5.1. Key Country Dynamics
7.5.5.2. Target Disease Prevalence
7.5.5.3. Competitive Scenario
7.5.5.4. Regulatory Framework
7.5.5.5. Argentina Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.6. MEA
7.6.1. SWOT Analysis
7.6.2. MEA Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.6.3. South Africa
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Competitive Scenario
7.6.3.4. Regulatory Framework
7.6.3.5. South Africa Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.6.4. Saudi Arabia
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Competitive Scenario
7.6.4.4. Regulatory Framework
7.6.4.5. Saudi Arabia Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.6.5. UAE
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Competitive Scenario
7.6.5.4. Regulatory Framework
7.6.5.5. UAE Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
7.6.6. Kuwait
7.6.6.1. Key Country Dynamics
7.6.6.2. Target Disease Prevalence
7.6.6.3. Competitive Scenario
7.6.6.4. Regulatory Framework
7.6.6.5. Kuwait Dupuytren’s Disease Market, 2018 - 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share Analysis, 2022
8.4. Company Profiles/Listing
8.4.1. Bayer AG.
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Novartis AG
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Pfizer Inc
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Nantong Jinghua Pharmaceutical Co., Ltd
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Actiza Pharmaceutical Private Limited
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Endo International plc
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Bristol-Meyers Squibb Company
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Spear Pharmaceuticals
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. GSK plc
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. AstraZeneca
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives
8.4.11. Hikma Pharmaceuticals PLC
8.4.11.1. Overview
8.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.11.3. Product Benchmarking
8.4.11.4. Strategic Initiatives
8.4.12. LEO Pharma A/S
8.4.12.1. Overview
8.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.12.3. Product Benchmarking
8.4.12.4. Strategic Initiatives
8.4.13. Fresenius Kabi AG
8.4.13.1. Overview
8.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.13.3. Product Benchmarking
8.4.13.4. Strategic Initiatives
LIST OF TABLES
TABLE 1 List of abbreviations
TABLE 2 Global Dupuytren’s disease market, by disease type, 2018 - 2030 (USD Million)
TABLE 3 Global Dupuytren’s disease market, by type, 2018 - 2030 (USD Million)
TABLE 4 Global Dupuytren’s disease market, by end-use, 2018 - 2030 (USD Million)
TABLE 5 Global Dupuytren’s disease market, by region, 2018 - 2030 (USD Million)
TABLE 6 North America Dupuytren’s disease market, by country, 2018 - 2030 (USD Million)
TABLE 7 North America Dupuytren’s disease market, by disease type, 2018 - 2030 (USD Million)
TABLE 8 North America Dupuytren’s disease market, by type, 2018 - 2030 (USD Million)
TABLE 9 North America Dupuytren’s disease market, by end-use, 2018 - 2030 (USD Million)
TABLE 10 U.S. Dupuytren’s disease market, by disease type, 2018 - 2030 (USD Million)
TABLE 11 U.S. Dupuytren’s disease market, by type, 2018 - 2030 (USD Million)
TABLE 12 U.S. Dupuytren’s disease market, by end-use, 2018 - 2030 (USD Million)
TABLE 13 Canada Dupuytren’s disease market, by disease type, 2018 - 2030 (USD Million)
TABLE 14 Canada Dupuytren’s disease market, by type, 2018 - 2030 (USD Million)
TABLE 15 Canada Dupuytren’s disease market, by end-use, 2018 - 2030 (USD Million)
TABLE 16 Europe Dupuytren’s disease, by country, 2018 - 2030 (USD Million)
TABLE 17 Europe Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 18 Europe Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 19 Europe Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 20 UK Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 21 UK Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 22 UK Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 23 Germany Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 24 Germany Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 25 Germany Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 26 France Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 27 France Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 28 France Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 29 Italy Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 30 Italy Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 31 Italy Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 32 Spain Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 33 Spain Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 34 Spain Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 35 Denmark Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 36 Denmark Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 37 Denmark Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 38 Sweden Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 39 Sweden Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 40 Sweden Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 41 Norway Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 42 Norway Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 43 Norway Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 44 Asia Pacific Dupuytren’s disease, by country, 2018 - 2030 (USD Million)
TABLE 45 Asia Pacific Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 46 Asia Pacific Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 47 Asia Pacific Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 48 Japan Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 49 Japan Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 50 Japan Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 51 China Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 52 China Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 53 China Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 54 India Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 55 India Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 56 India Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 57 Australia Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 58 Australia Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 59 Australia Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 60 Thailand Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 61 Thailand Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 62 Thailand Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 63 South Korea Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 64 South Korea Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 65 South Korea Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 66 Latin America Dupuytren’s disease, by country, 2018 - 2030 (USD Million)
TABLE 67 Latin America Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 68 Latin America Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 69 Latin America Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 70 Brazil Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 71 Brazil Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 72 Brazil Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 73 Mexico Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 74 Mexico Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 75 Mexico Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 76 Argentina Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 77 Argentina Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 78 Argentina Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 79 Middle East & Africa Dupuytren’s disease, by country, 2018 - 2030 (USD Million)
TABLE 80 Middle East & Africa Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 81 Middle East & Africa Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 82 Middle East & Africa Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 83 South Africa Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 84 South Africa Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 85 South Africa Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 86 Saudi Arabia Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 87 Saudi Arabia Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 88 Saudi Arabia Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 89 UAE Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 90 UAE Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 91 UAE Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 92 Kuwait Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 93 Kuwait Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 94 Kuwait Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 1 List of abbreviations
TABLE 2 Global Dupuytren’s disease market, by disease type, 2018 - 2030 (USD Million)
TABLE 3 Global Dupuytren’s disease market, by type, 2018 - 2030 (USD Million)
TABLE 4 Global Dupuytren’s disease market, by end-use, 2018 - 2030 (USD Million)
TABLE 5 Global Dupuytren’s disease market, by region, 2018 - 2030 (USD Million)
TABLE 6 North America Dupuytren’s disease market, by country, 2018 - 2030 (USD Million)
TABLE 7 North America Dupuytren’s disease market, by disease type, 2018 - 2030 (USD Million)
TABLE 8 North America Dupuytren’s disease market, by type, 2018 - 2030 (USD Million)
TABLE 9 North America Dupuytren’s disease market, by end-use, 2018 - 2030 (USD Million)
TABLE 10 U.S. Dupuytren’s disease market, by disease type, 2018 - 2030 (USD Million)
TABLE 11 U.S. Dupuytren’s disease market, by type, 2018 - 2030 (USD Million)
TABLE 12 U.S. Dupuytren’s disease market, by end-use, 2018 - 2030 (USD Million)
TABLE 13 Canada Dupuytren’s disease market, by disease type, 2018 - 2030 (USD Million)
TABLE 14 Canada Dupuytren’s disease market, by type, 2018 - 2030 (USD Million)
TABLE 15 Canada Dupuytren’s disease market, by end-use, 2018 - 2030 (USD Million)
TABLE 16 Europe Dupuytren’s disease, by country, 2018 - 2030 (USD Million)
TABLE 17 Europe Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 18 Europe Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 19 Europe Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 20 UK Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 21 UK Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 22 UK Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 23 Germany Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 24 Germany Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 25 Germany Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 26 France Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 27 France Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 28 France Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 29 Italy Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 30 Italy Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 31 Italy Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 32 Spain Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 33 Spain Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 34 Spain Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 35 Denmark Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 36 Denmark Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 37 Denmark Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 38 Sweden Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 39 Sweden Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 40 Sweden Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 41 Norway Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 42 Norway Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 43 Norway Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 44 Asia Pacific Dupuytren’s disease, by country, 2018 - 2030 (USD Million)
TABLE 45 Asia Pacific Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 46 Asia Pacific Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 47 Asia Pacific Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 48 Japan Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 49 Japan Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 50 Japan Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 51 China Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 52 China Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 53 China Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 54 India Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 55 India Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 56 India Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 57 Australia Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 58 Australia Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 59 Australia Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 60 Thailand Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 61 Thailand Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 62 Thailand Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 63 South Korea Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 64 South Korea Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 65 South Korea Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 66 Latin America Dupuytren’s disease, by country, 2018 - 2030 (USD Million)
TABLE 67 Latin America Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 68 Latin America Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 69 Latin America Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 70 Brazil Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 71 Brazil Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 72 Brazil Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 73 Mexico Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 74 Mexico Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 75 Mexico Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 76 Argentina Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 77 Argentina Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 78 Argentina Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 79 Middle East & Africa Dupuytren’s disease, by country, 2018 - 2030 (USD Million)
TABLE 80 Middle East & Africa Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 81 Middle East & Africa Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 82 Middle East & Africa Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 83 South Africa Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 84 South Africa Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 85 South Africa Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 86 Saudi Arabia Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 87 Saudi Arabia Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 88 Saudi Arabia Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 89 UAE Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 90 UAE Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 91 UAE Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
TABLE 92 Kuwait Dupuytren’s disease, by disease type, 2018 - 2030 (USD Million)
TABLE 93 Kuwait Dupuytren’s disease, by type, 2018 - 2030 (USD Million)
TABLE 94 Kuwait Dupuytren’s disease, by end-use, 2018 - 2030 (USD Million)
LIST OF FIGURES
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain-based sizing & forecasting
FIG. 6 Market formulation & validation
FIG. 7 Dupuytren's disease market segmentation
FIG. 8 Market snapshot, 2022
FIG. 9 Market trends & outlook
FIG. 10 Market driver relevance analysis (current & future impact)
FIG. 11 Market restraint relevance analysis (current & future impact)
FIG. 12 SWOT analysis, by factor (political & legal, economic, and technological)
FIG. 13 Porter’s five forces analysis
FIG. 14 Market penetration & growth prospect mapping, 2022
FIG. 15 Global Dupuytren’s disease market: Disease type movement analysis
FIG. 16 Global Dupuytren’s disease market, for disease I, 2018 - 2030 (USD Million)
FIG. 17 Global Dupuytren’s disease market, for disease II, 2018 - 2030 (USD Million)
FIG. 18 Global Dupuytren’s disease market, for disease III, 2018 - 2030 (USD Million)
FIG. 19 Global Dupuytren’s disease market: type movement analysis
FIG. 20 Global Dupuytren’s disease market, for diagnosis, 2018 - 2030 (USD Million)
FIG. 21 Global Dupuytren’s disease market, for physical examination, 2018 - 2030 (USD Million)
FIG. 22 Global Dupuytren’s disease market, for X-ray, 2018 - 2030 (USD Million)
FIG. 23 Global Dupuytren’s disease market, for treatment, 2018 - 2030 (USD Million)
FIG. 24 Global Dupuytren’s disease market, for surgery, 2018 - 2030 (USD Million)
FIG. 25 Global Dupuytren’s disease market, for radiation therapy, 2018 - 2030 (USD Million)
FIG. 26 Global Dupuytren’s disease market, for needle aponeurotomy, 2018 - 2030 (USD Million)
FIG. 27 Global Dupuytren’s disease market, for steroid shot, 2018 - 2030 (USD Million)
FIG. 28 Global Dupuytren’s disease market, for enzyme injection, 2018 - 2030 (USD Million)
FIG. 29 Global Dupuytren’s disease market, for occupational therapy, 2018 - 2030 (USD Million)
FIG. 30 Global Dupuytren’s disease market, for others, 2018 - 2030 (USD Million)
FIG. 31 Global Dupuytren’s disease market: End-use movement analysis
FIG. 32 Global Dupuytren’s disease market, for hospitals, 2018 - 2030 (USD Million)
FIG. 33 Global Dupuytren’s disease market, for clinics, 2018 - 2030 (USD Million)
FIG. 34 Global Dupuytren’s disease market, for academic & research institutes, 2018 - 2030 (USD Million)
FIG. 35 Global Dupuytren’s disease market, for others, 2018 - 2030 (USD Million)
FIG. 36 Regional marketplace: Key takeaways
FIG. 37 Regional outlook, 2022 & 2030
FIG. 38 Global Dupuytren’s disease market: Region movement analysis
FIG. 39 North America Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 40 U.S. Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 41 Canada Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 42 Europe Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 43 Germany Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 44 UK Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 45 France Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 46 Italy Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 47 Spain Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 48 Denmark Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 49 Sweden Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 50 Norway Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 51 Asia Pacific Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 52 Japan Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 53 China Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 54 India Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 55 Australia Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 56 South Korea Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 57 Thailand Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 58 Latin America Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 59 Brazil Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 60 Mexico Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 61 Argentina Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 62 Middle East and Africa Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 63 South Africa Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 64 Saudi Arabia Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 65 UAE Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 66 Kuwait Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain-based sizing & forecasting
FIG. 6 Market formulation & validation
FIG. 7 Dupuytren's disease market segmentation
FIG. 8 Market snapshot, 2022
FIG. 9 Market trends & outlook
FIG. 10 Market driver relevance analysis (current & future impact)
FIG. 11 Market restraint relevance analysis (current & future impact)
FIG. 12 SWOT analysis, by factor (political & legal, economic, and technological)
FIG. 13 Porter’s five forces analysis
FIG. 14 Market penetration & growth prospect mapping, 2022
FIG. 15 Global Dupuytren’s disease market: Disease type movement analysis
FIG. 16 Global Dupuytren’s disease market, for disease I, 2018 - 2030 (USD Million)
FIG. 17 Global Dupuytren’s disease market, for disease II, 2018 - 2030 (USD Million)
FIG. 18 Global Dupuytren’s disease market, for disease III, 2018 - 2030 (USD Million)
FIG. 19 Global Dupuytren’s disease market: type movement analysis
FIG. 20 Global Dupuytren’s disease market, for diagnosis, 2018 - 2030 (USD Million)
FIG. 21 Global Dupuytren’s disease market, for physical examination, 2018 - 2030 (USD Million)
FIG. 22 Global Dupuytren’s disease market, for X-ray, 2018 - 2030 (USD Million)
FIG. 23 Global Dupuytren’s disease market, for treatment, 2018 - 2030 (USD Million)
FIG. 24 Global Dupuytren’s disease market, for surgery, 2018 - 2030 (USD Million)
FIG. 25 Global Dupuytren’s disease market, for radiation therapy, 2018 - 2030 (USD Million)
FIG. 26 Global Dupuytren’s disease market, for needle aponeurotomy, 2018 - 2030 (USD Million)
FIG. 27 Global Dupuytren’s disease market, for steroid shot, 2018 - 2030 (USD Million)
FIG. 28 Global Dupuytren’s disease market, for enzyme injection, 2018 - 2030 (USD Million)
FIG. 29 Global Dupuytren’s disease market, for occupational therapy, 2018 - 2030 (USD Million)
FIG. 30 Global Dupuytren’s disease market, for others, 2018 - 2030 (USD Million)
FIG. 31 Global Dupuytren’s disease market: End-use movement analysis
FIG. 32 Global Dupuytren’s disease market, for hospitals, 2018 - 2030 (USD Million)
FIG. 33 Global Dupuytren’s disease market, for clinics, 2018 - 2030 (USD Million)
FIG. 34 Global Dupuytren’s disease market, for academic & research institutes, 2018 - 2030 (USD Million)
FIG. 35 Global Dupuytren’s disease market, for others, 2018 - 2030 (USD Million)
FIG. 36 Regional marketplace: Key takeaways
FIG. 37 Regional outlook, 2022 & 2030
FIG. 38 Global Dupuytren’s disease market: Region movement analysis
FIG. 39 North America Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 40 U.S. Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 41 Canada Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 42 Europe Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 43 Germany Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 44 UK Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 45 France Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 46 Italy Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 47 Spain Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 48 Denmark Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 49 Sweden Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 50 Norway Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 51 Asia Pacific Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 52 Japan Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 53 China Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 54 India Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 55 Australia Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 56 South Korea Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 57 Thailand Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 58 Latin America Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 59 Brazil Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 60 Mexico Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 61 Argentina Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 62 Middle East and Africa Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 63 South Africa Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 64 Saudi Arabia Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 65 UAE Dupuytren’s disease market, 2018 - 2030 (USD Million)
FIG. 66 Kuwait Dupuytren’s disease market, 2018 - 2030 (USD Million)
